Evidence map›Paper›PMID 24559044›Full record

ArticleJournal of nanobiotechnology2014

Reduction of conspicuous facial pores by topical fullerene: possible role in the suppression of PGE2 production in the skin.

Shigeki Inui, Ayako Mori, Masayuki Ito, Sayuri Hyodo, Satoshi Itami

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Magnolin Mitigates Skin Ageing Through the CXCL10/p38 Signalling Pathway.Journal of cellular and molecular medicine · 2025
    Article
  2. Efficacy ofCurrent issues in molecular biology · 2024
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shigeki InuiDepartment of Regenerative Dermatology, Graduate School of Medicine, Osaka University, 2-2, G2, Yamadaoka, Suita -shi, Osaka 565-0871, Japan. inui@r-derma.med.osaka-u.ac.jp.
Ayako Mori
Masayuki Ito
Sayuri Hyodo
Satoshi Itami
Osaka University · JPDMG Mori (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConspicuous facial pores are therapeutic targets for cosmeceuticals. Here we examine the effect of topical fullerene on conspicuous facial pores using a new image analyser called the VISIA® system. Ten healthy Japanese females participated in this study, and they received applications of 1% fullerene lotion to the face twice a day for 8 weeks.

findingsFullerene lotion significantly decreased conspicuous pores by 17.6% (p < 0.05, Wilcoxon signed-rank test) after an 8-week treatment. A self-administered questionnaire indicated that this reduction achieved cosmetically appreciable effects. In addition, to investigate the mechanism of effect of fullerene, we examined its effect on UVB-induced prostaglandin E2 (PGE2) production in reconstructed human epidermis (RhE). The results showed that irradiation of RhE with 1000 mJ/cm2 increased PGE2 production by 62.3% (p < 0.05, Mann-Whitney U-test) and the addition of 28 μM fullerene significantly suppressed the UVB-induced PGE2 production by 18.3% (p < 0.05).

conclusionsFullerene lotion significantly decreases conspicuous facial pores after an 8-week treatment possibly through the suppression of PGE2 production in the epidermis.

Indexed as

Administration, TopicalAdultAgedCosmeticsDinoprostoneFemaleFullerenesHumansMiddle AgedSkinUltraviolet RaysCosmeticsDinoprostoneFullerenes

Identifiers

PMID24559044
PMCPMC3940024
OpenAlexW2104366647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.